Migraine

>

Latest News

Fremanezumab Label Expanded for Treatment of Episodic Migraine in Children Aged 6 to 17 Years
Fremanezumab Label Expanded for Treatment of Episodic Migraine in Children Aged 6 to 17 Years

August 6th 2025

Fremanezumab is now the only CGRP antagonist indicated for prevention of migraine in adults and preventive treatment of episodic migraine in pediatric patients.

Atogepant Superior to Topiramate for Migraine Prevention in Phase 3 Head-to-Head TEMPLE Study / image credit ©mopic/shutterstock.com
Atogepant Superior to Topiramate for Migraine Prevention in Phase 3 Head-to-Head TEMPLE Study

June 18th 2025

Fremanezumab Demonstrates Dual Benefits in Adults with Migraine and Depression
Fremanezumab Demonstrates Dual Benefits in Adults with Migraine and Depression

May 6th 2025

FDA Approves Atzumi (Dihydroergotamine) Nasal Powder for Acute Treatment of Migraine / image credit ©Waldenmarus/stock.adobe.com
FDA Approves STS101 (Dihydroergotamine) Nasal Powder for Acute Treatment of Migraine

May 1st 2025

For Patients with Migraine who do Not Initially Respond to CGRP Inhibitor Therapy, Switching mAbs May Provide Relief / image credit courtesy of Fundación Jiménez Díaz University Hospital
Switching Anti-CGRP Monoclonal Antibody Therapy in Nonresponders with Migraine May Reduce Monthly Headache Days

April 29th 2025

More News

Site Logo

Menstrual Migraine: How "Mini-Prophylaxis" Can Work for Your Patient

Loretta Mueller, DO
May 1st 2002

Migraine is an episodic, often debilitatingcondition that affects women moreoften than men. Twenty-eight millionAmericans suffer from migraineheadaches-and nearly 75% of theseare women.1 Unlike other chronic painconditions, migraine has its peakprevalence during the years of greatestproductivity, when most women arejuggling family responsibilities andcareers.2 Many women are particularlysusceptible to migraine attacks justbefore and during menses.

<1
...
678910
© 2025 MJH Life Sciences

All rights reserved.